1. Home
  2. BIOA vs RMAX Comparison

BIOA vs RMAX Comparison

Compare BIOA & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIOA
  • RMAX
  • Stock Information
  • Founded
  • BIOA 2015
  • RMAX 1973
  • Country
  • BIOA United States
  • RMAX United States
  • Employees
  • BIOA N/A
  • RMAX N/A
  • Industry
  • BIOA Biotechnology: Pharmaceutical Preparations
  • RMAX Real Estate
  • Sector
  • BIOA Health Care
  • RMAX Finance
  • Exchange
  • BIOA Nasdaq
  • RMAX Nasdaq
  • Market Cap
  • BIOA 177.1M
  • RMAX 200.2M
  • IPO Year
  • BIOA 2024
  • RMAX 2013
  • Fundamental
  • Price
  • BIOA $5.14
  • RMAX $9.99
  • Analyst Decision
  • BIOA Hold
  • RMAX Hold
  • Analyst Count
  • BIOA 3
  • RMAX 4
  • Target Price
  • BIOA $18.00
  • RMAX $9.17
  • AVG Volume (30 Days)
  • BIOA 959.0K
  • RMAX 161.7K
  • Earning Date
  • BIOA 02-15-2025
  • RMAX 02-20-2025
  • Dividend Yield
  • BIOA N/A
  • RMAX N/A
  • EPS Growth
  • BIOA N/A
  • RMAX N/A
  • EPS
  • BIOA N/A
  • RMAX N/A
  • Revenue
  • BIOA N/A
  • RMAX $311,818,000.00
  • Revenue This Year
  • BIOA N/A
  • RMAX N/A
  • Revenue Next Year
  • BIOA N/A
  • RMAX $0.85
  • P/E Ratio
  • BIOA N/A
  • RMAX N/A
  • Revenue Growth
  • BIOA N/A
  • RMAX N/A
  • 52 Week Low
  • BIOA $3.85
  • RMAX $6.94
  • 52 Week High
  • BIOA $26.62
  • RMAX $14.31
  • Technical
  • Relative Strength Index (RSI)
  • BIOA N/A
  • RMAX 39.50
  • Support Level
  • BIOA N/A
  • RMAX $10.25
  • Resistance Level
  • BIOA N/A
  • RMAX $10.28
  • Average True Range (ATR)
  • BIOA 0.00
  • RMAX 0.42
  • MACD
  • BIOA 0.00
  • RMAX 0.00
  • Stochastic Oscillator
  • BIOA 0.00
  • RMAX 46.45

About BIOA BioAge Labs Inc. Common Stock

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

About RMAX RE/MAX Holdings Inc.

RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.

Share on Social Networks: